Alimera Sciences Company Profile (NASDAQ:ALIM)

About Alimera Sciences

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALIM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.22
  • 50 Day Moving Average: $1.18
  • 200 Day Moving Average: $1.34
  • 52-Week Range: $64,862,000.00 - $1.01
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.13
  • P/E Growth: 0.00
  • Market Cap: $79.13M
  • Outstanding Shares: 64,862,000
  • Beta: 3.13
Profitability:
  • Net Margins: -128.77%
  • Return on Assets: -55.69%
Debt:
  • Debt-to-Equity Ratio: -0.87%
  • Current Ratio: 6.57%
  • Quick Ratio: 6.46%
Additional Links:
Companies Related to Alimera Sciences:

Analyst Ratings

Consensus Ratings for Alimera Sciences (NASDAQ:ALIM) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (227.87% upside)

Analysts' Ratings History for Alimera Sciences (NASDAQ:ALIM)
Show:
DateFirmActionRatingPrice TargetDetails
9/16/2016Cowen and CompanyUpgradeMarket Perform -> Outperform$3.00View Rating Details
3/4/2016Cantor FitzgeraldLower Price TargetBuy$6.00 -> $5.00View Rating Details
11/26/2015Credit Suisse GroupLower Price Target$5.00 -> $4.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Alimera Sciences (NASDAQ:ALIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017        
11/2/2016Q316($0.11)($0.16)$10.53 million$8.30 millionViewN/AView Earnings Details
8/3/2016Q2($0.19)($0.17)$8.42 million$3.80 millionViewN/AView Earnings Details
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details
11/5/2015Q315($0.21)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details
3/4/2015Q414$0.17($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details
11/11/2013Q313($0.30)($0.26)$0.38 million$0.76 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.30)$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.15 EPS

Dividends

Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alimera Sciences (NASDAQ:ALIM)
Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 53.26%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Richard S Eiswirth JrInsiderSell51,471$1.51$77,721.21View SEC Filing  
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.07View SEC Filing  
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.39View SEC Filing  
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.25View SEC Filing  
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.00View SEC Filing  
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.00View SEC Filing  
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.00View SEC Filing  
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
DateHeadline
News IconUnusual Volume Spotted in Alimera Sciences, Inc. (NASDAQ:ALIM) Stock - Winfield Review (NASDAQ:ALIM)
winfieldreview.com - February 16 at 3:32 PM
News IconReading the Numbers on Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Baxter Review (NASDAQ:ALIM)
baxternewsreview.com - February 16 at 8:07 AM
News IconStock Levels in Review for Alimera Sciences Inc. (ALIM) - Rives Journal (NASDAQ:ALIM)
rivesjournal.com - February 14 at 1:56 AM
News IconMarket Rover: Looking at Levels on Shares of Alimera Sciences Inc. (ALIM) - Davidson Register (NASDAQ:ALIM)
davidsonregister.com - February 10 at 3:54 PM
seekingalpha.com logoAlimera Sciences: 2017 Outlook - Seeking Alpha (NASDAQ:ALIM)
seekingalpha.com - February 10 at 3:54 PM
News IconCompany Watch: Viewing Levels for Alimera Sciences Inc. (ALIM) - Piedmont Register (NASDAQ:ALIM)
piedmontregister.com - February 8 at 8:45 PM
News IconAlimera Sciences, Inc. (NASDAQ:ALIM) shows weekly volitility of 5.46% - The Newburgh Press (NASDAQ:ALIM)
newburghpress.com - February 8 at 3:37 PM
streetinsider.com logoAlimera Sciences (ALIM) Announces Pricing and Reimbursement Decree for ILUVIEN in Italy - StreetInsider.com (NASDAQ:ALIM)
www.streetinsider.com - February 8 at 3:37 PM
News IconIluvien receives reimbursement decree in Italy (NASDAQ:ALIM)
www.healio.com - February 8 at 1:57 AM
News IconFast-Track Approval of Pipeline Drugs and Rise in R&D Initiatives are Expected to Drive the Global Uveitis Treatment Market (NASDAQ:ALIM)
www.medgadget.com - February 7 at 1:33 AM
reuters.com logoBRIEF-Alimera Sciences says its unit Alimera Sciences Ltd received pricing, reimbursement decree for ILUVIEN on Jan. 11 (NASDAQ:ALIM)
www.reuters.com - February 7 at 1:33 AM
News IconAlimera Sciences Announces the Reimbursement of ILUVIEN® in Italy - Satellite PR News (press release) (NASDAQ:ALIM)
www.satprnews.com - February 6 at 8:32 PM
News IconErratic Volume Takes A Hold of This Stock: Alimera Sciences, Inc. (NASDAQ:ALIM) - Davidson Register (NASDAQ:ALIM)
davidsonregister.com - February 6 at 8:32 PM
finance.yahoo.com logoAlimera Sciences Announces the Reimbursement of ILUVIEN® in Italy (NASDAQ:ALIM)
finance.yahoo.com - February 6 at 3:30 PM
finance.yahoo.com logo9:01 am Alimera Sciences received the pricing and reimbursement decree for ILUVIEN from Agenzia Italiana del Farmaco on January 11, 2017 (NASDAQ:ALIM)
finance.yahoo.com - February 6 at 3:30 PM
News IconTrading Radar: Zooming in on Shares of Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - February 3 at 3:37 PM
News IconInvesting Focus: Indicators in View on Shares of Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - February 2 at 3:26 PM
News IconStock Tracker: Trend Analysis on Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - February 1 at 3:31 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Alimera Sciences, Inc. (NASDAQ:ALIM) - Nelson Research (NASDAQ:ALIM)
nelsonobserver.com - February 1 at 3:31 PM
News IconCan This Stock Make a Ripple in the Market: Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - February 1 at 3:31 PM
News IconChart Inspection on Shares of Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 31 at 3:36 PM
News IconShares in Focus: Alimera Sciences, Inc. (NASDAQ:ALIM) - The Tribune (NASDAQ:ALIM)
lakecitytribune.com - January 31 at 3:36 PM
News IconPlacing This Stock in the Hotbed: Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 31 at 3:36 PM
News IconWhat's Alimera Sciences Inc (ALIM) Downside After Forming Bearish Multiple Bottom Chart Pattern? - The Randolph Guide (NASDAQ:ALIM)
randolphguide.com - January 30 at 8:40 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 30 at 3:38 PM
News IconAverage Directional Index Review for Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 27 at 3:35 PM
News IconWilliams %R, RSI, and ADX Update for Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 26 at 3:43 PM
News IconVolatility Watch on Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - The Tribune (NASDAQ:ALIM)
lakecitytribune.com - January 26 at 3:43 PM
News IconCan This Stock Price Climb The Ladder: Alimera Sciences, Inc ... - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 26 at 3:43 PM
News IconTrading Views: Checking the Numbers for Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 25 at 3:32 PM
News IconTechnical Toolbox: Investor Focus on Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 25 at 1:49 AM
News IconF-Score in Review on Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - The Tribune (NASDAQ:ALIM)
lakecitytribune.com - January 24 at 3:48 PM
News IconBoom or Bust? Is there any value in Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 24 at 1:38 AM
streetinsider.com logoForm 4 ALIMERA SCIENCES INC For: Jan 20 Filed by: Ashman Philip - StreetInsider.com (NASDAQ:ALIM)
www.streetinsider.com - January 24 at 1:38 AM
News IconInvestor Sphere: Keeping an Eye on Levels for Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 23 at 3:29 PM
News IconDiabetic Macular Edema Market Forecast and Segments, 2017-2027 (NASDAQ:ALIM)
reports.pr-inside.com - January 23 at 1:29 AM
News IconUveitis Treatment Market: Emerging Trends and New Technologies Research 2016 - 2024 (NASDAQ:ALIM)
reports.pr-inside.com - January 20 at 3:59 PM
News IconFluocinolone Implant Slows Diabetic Retinopathy in Patients With Macular Edema (NASDAQ:ALIM)
www.medscape.com - January 19 at 8:50 PM
News IconTracking CCI Levels on Shares of Alimera Sciences Inc. (ALIM) - Sherwood Daily (NASDAQ:ALIM)
sherwooddaily.com - January 18 at 2:09 AM
News IconGlobal Diabetic Retinopathy Treatment Market by Region, Data Validation, Analysis and Forecast 2022 (NASDAQ:ALIM)
www.emailwire.com - January 17 at 4:07 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Alimera ... - Wall Street Beacon (NASDAQ:ALIM)
wsbeacon.com - January 15 at 3:27 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Alimera Sciences, Inc. (NASDAQ:ALIM) - Wall Street Beacon (NASDAQ:ALIM)
wsbeacon.com - January 14 at 3:26 PM
News IconIs There a Catalyst Out There For Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 13 at 8:53 PM
News IconBreaking Short Interest: Alimera Sciences Incorporated (NASDAQ:ALIM) Can't Be More Risky. Short Interest Increased - Baxley Report (NASDAQ:ALIM)
baxleyreport.com - January 13 at 3:50 PM
News IconStock Edging Lower Out Of The Gate: Alimera Sciences, Inc. (NASDAQ:ALIM) - Wall Street Beacon (NASDAQ:ALIM)
wsbeacon.com - January 12 at 3:29 PM
News IconAre Cagey Traders Interested in These Shares: Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 12 at 3:29 PM
News IconInvestors Keen on a Bargain are Looking at Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 11 at 8:47 PM
News IconGlobal Uveitis Treatment Market Revenues Poised to Reach US$ 847.8 Mn by 2024 - Persistence Market Research (NASDAQ:ALIM)
www.prnewswire.co.uk - January 11 at 3:46 PM
capitalcube.com logoETFs with exposure to Alimera Sciences, Inc. : January 11, 2017 (NASDAQ:ALIM)
www.capitalcube.com - January 11 at 3:45 PM
News IconStock ready to Pivot? Focus on Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Prospect Journal (NASDAQ:ALIM)
prospectjournal.com - January 10 at 3:29 PM

Social

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?

2 brokers have issued 1-year target prices for Alimera Sciences' stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Alimera Sciences' share price to reach $4.00 in the next year.

When will Alimera Sciences announce their earnings?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:

  • According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (1/17/2017)

  • Cowen and Company analysts commented, "ALIM pre-announced 2Q16 revenue of $9.3-9.5M ahead of our estimate of $7.8M." (7/26/2016)

Who owns Alimera Sciences stock?

Alimera Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Patrick Lee, MD (22.73%), Deerfield Management Co. (9.06%), Stonepine Capital Management LLC (7.12%), Armistice Capital LLC (4.93%), Palo Alto Investors LLC (4.65%) and North Run Capital LP (2.67%). Company insiders that own Alimera Sciences stock include C Daniel Myers, Calvin W Roberts, James E Flynn, Kenneth Green, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr.

Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?

Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including North Run Capital LP. Company insiders that have sold Alimera Sciences stock in the last year include LP Bavp and Richard S Eiswirth Jr.

Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?

Alimera Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Armistice Capital LLC and Alyeska Investment Group L.P.. Company insiders that have bought Alimera Sciences stock in the last two years include Calvin W Roberts, James E Flynn and Richard S Eiswirth Jr.

How do I buy Alimera Sciences stock?

Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alimera Sciences stock cost?

One share of Alimera Sciences stock can currently be purchased for approximately $1.22.

Alimera Sciences (NASDAQ:ALIM) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Alimera Sciences (NASDAQ:ALIM)

Earnings History Chart

Earnings by Quarter for Alimera Sciences (NASDAQ:ALIM)

Dividend History Chart

Dividend Payments by Quarter for Alimera Sciences (NASDAQ:ALIM)

Last Updated on 2/19/2017 by MarketBeat.com Staff